Effect on Exercise Endurance and Lung Hyperinflation of Tiotropium + Olodaterol in COPD Patients.

Model scores of the 29,894 trials active now.

Model score 5% for any early termination, 1% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 6% of the time (528 trials).

Finished trial that started 2008–2014: scored by a model trained without any trial from its start year, so its own outcome was never used.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2013-11-30. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Design: crossover (lowers risk) · Design
• Wording of the registration (title, summary, criteria) (lowers risk) · Wording Phrases that raised it: effectplacebodouble blinddiagnosisexercise
  Phrases that lowered it: patients whoulncopdpatients withcriteria patients
• Minimum age: 40 (lowers risk) · Who can join
• Accepts healthy volunteers: No (raises risk) · Who can join
• Sponsor's past termination rate: 6.2% (lowers risk) · Sponsor's track record
• Phase: 3 (lowers risk) · Design
• Has a data monitoring committee: not given (lowers risk) · Design
• Drug's FAERS reports with a death: 7.1% (lowers risk) · Drug's FDA history
• Drug's FAERS reports marked serious: 36.5% (lowers risk) · Drug's FDA history
• Trials the sponsor started in the prior 2 years: 166 (lowers risk) · Sponsor's track record
• Disease area, cancer: No (lowers risk) · Disease area
• Sponsor type: industry (lowers risk) · Sponsor's track record
• Sponsor's past trials: 113 (lowers risk) · Sponsor's track record
• Drug's FAERS reports in the prior 12 months: 6579 (lowers risk) · Drug's FDA history
• Disease area, neurology: No (lowers risk) · Disease area
• Blinding: double (raises risk) · Design
• Maximum age: 75 (lowers risk) · Who can join
• Drug's FAERS reports before start: 32811 (lowers risk) · Drug's FDA history

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Effect on Exercise Endurance and Lung Hyperinflation of Tiotropium + Olodaterol in COPD Patients NCT01533922 · started 2012 · scored riskier than 4% of active trials completed
• Co-administration of Olodaterol Respimat® and Tiotropium Handihaler® NCT01696058 · started 2012 · scored riskier than 4% of active trials completed
• Co-administration of Olodaterol Respimat® and Tiotropium Handihaler® NCT01694771 · started 2012 · scored riskier than 4% of active trials completed
• To Evaluate the Effect of Inhaled Medication Together With Exercise and Activity Training on Exercise Capacity and Daily Activities in Patients With Chronic Lung Disease With Obstruction of Airways NCT02085161 · started 2014 · scored riskier than 5% of active trials completed
• A Study to Determine the Effect of Tiotropium + Olodaterol Fixed Dose Combination on Exercise Endurance Time During Constant Work Rate Cycle Ergometry Test in COPD NCT01525615 · started 2012 · scored riskier than 5% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.